Over-expression of extracellular matrix metalloproteinase inducer in prostate cancer is associated with high risk of prostate-speci c antigen relapse a er radical prostatectomy
Prostate cancer (PCa) is the second most frequent cause of cancer-related death for Western men. Its incidence is continuously rising, with over 200,000 new cancers and 35,000-40,000 deaths per year [1, 2] . Carcinogenesis is a multi-step process, involving both genetic insults to epithelial cells and changes in epithelial-stromal interactions [3] . Despite current improvements in diagnostic and therapeutic methods, many patients with PCa develop metastases and the prognosis rate of this disease varies greatly for patients with di erent clinical stages and pathological grades. e conventional prognostic markers, such as clinical stage, tumor grade and preoperative prostatespeci c antigen (PSA), show limited ability to predict the clinical outcome. us, the search for novel biomarkers that are capable of discriminating PCa with low and high aggressiveness and recurrence potential is an important goal in this eld.
e degradation of the extracellular matrix (ECM) surrounding primary tumors and metastases is critical for the invasion and metastasis of epithelial tumor cells [4] . Matrix metalloproteinases (MMPs) expression by stromal [5] and endothelial cells [6] are regulated by various soluble or cell-bound factors, such as extracellular Matrix Metalloproteinase Inducer (EMMPRIN), which is a member of the immunoglobulin family. EMMPRIN has been demonstrated to be involved in tumor invasion and metastasis via stimulating matrix metalloproteinase synthesis in neighboring broblasts, in malignant cell proliferation via the activation of ERK1/2 and p38 mitogen-activated protein kinases, in enhancing angiogenesis via vascular endothelial growth factor, in inducing chemoresistant tumor cells via the production of hyaluronan, and in resistance of cancer cells to anoikis through inhibition of Bim [7] [8] [9] [10] [11] . Some research has demonstrated that EMMPRIN is association with the outcome of breast cancer [12] and that EMMPRIN expression is associated with the overall survival of patients with PCa [13] [14] . In view of these results, the aim of this study was to determine the expression of EMMPRIN at the transcriptional and translational levels, and to clarify the correlation between EMMPRIN expression, in a large cohort of PCa patients, and PSA relapse-free time a er radical prostatectomy to further evaluate the validity of EMMPRIN as a diagnostic or prognostic marker.
Materials and Methods

Patients and Tissue Samples
is study was approved by the Ethics Committee of Guangzhou First Municipal People's Hospital, A liated Guangzhou Medical College. Informed consent was obtained from all of the patients. All specimens were handled and made anonymous according to the ethical and legal standards.
ree hundred patients with PCa, whose detailed clinical and pathological information was available, were selected from Department of Pathology at Massachusetts General Hospital (MA, USA) and Department of Urology at Guangzhou First Municipal Peoples' Hospital in Guangzhou Medical College (Guangdong, China). e clinical characteristics of these patients were listed in Table 1 . None of the patients recruited in this study had chemotherapy or radiotherapy before the surgery. All of the tissue samples were obtained during transurethral resection prostate and suprapubic prostatectomy. Surgically-resected tissues were para n-embedded, sectioned at 3 µm thickness and stained. e pathological diagnosis was performed preoperatively and con rmed postoperatively. Two or more pathologists classi ed their stages according to American Joint Committee on cancer (AJCC) guidelines [15] . For 20 of the subjects, both cancerous and adjacent normal prostate tissue samples were taken and the normal tissue used as control samples for the immunohistochemical analysis.
Bi et al. EMMPRIN in PCa is associated with PSA relapse e follow-up time was de ned as the interval from the date of surgery to the latest measurement of PSA levels. e study end point was the time of PSA relapse and was de ned as two consecutive rising serum PSA values greater than 0.2 ng/ ml [16] .
uantitative real-time PCR
Total RNA of 20 pairs of adjacent normal and cancerous prostate tissues was prepared and reverse transcribed, and quantitative real-time PCR (QRT-PCR) was carried out as previously described [17] . e primers 5'-TGG CCT TCA CGT TCC TGA GT -3' and 5'-GTC ATC TGC ATC CAC CGT GT -3' were used to amplify 215 bp transcripts of EMMPRIN, and the primers 5'-GTG CCA CCA GAC AGC ACT GTG TTG -3' and 5'-TGG AGA AGA GCT ATG AGC TGC CTG -3' were used to amplify 202 bp transcripts of β-actin. Productspeci c ampli cation was con rmed by melting curve analysis and agarose gel electrophoresis. Serial dilutions were made using previously generated PCR products, assigned arbitrary values corresponding to the dilutions, and used to construct relative standard curves for EMMPRIN. Targets were normalized using β-actin as internal standards.
Immunohistochemistry analysis
HAb 18G/CD147 (EMMPIN) monoclonal antibody was collected by the Biological Research Center (Fourth Military Medical University, Xi'an, China). e antibody speci city had been demonstrated in our previous studies [13, 14, 17, 18] . e specimens were xed in 10% neutral bu ered formalin and subsequently embedded in para n. e para nembedded tissues were cut at 3 μm and then depara nized with xylene and rehydrated for further H&E or peroxidase (DAB) immunohistochemistry staining employing DAKO EnVision System (Dako Diagnostics, Zug, Switzerland). Following a simple proteolytic digestion and a peroxidase blocking, the tissue slides were incubated with the primary antibody against respective target protein at a dilution of 1:1000 overnight at 4ºC. A er washing, peroxidase labeled polymer and substrate-chromogen were then employed in order to visualize the staining of the interested proteins. In each immunohistochemistry run, negative controls were carried out by omitting the primary antibody. EMMPIN overexpression, con rmed by Western blotting. was used as a positive control.
Following hematoxylin counterstaining, the results from the immunostaining was scored by two independent experienced pathologists, who were blinded to the clinicopathological data and clinical outcomes of the patients. e scores of the two pathologists were compared and any discrepant samples were re-examined by both pathologists to achieve a consensus score. e number of positive-staining tumor cells showing immunoreactivity on the cell membranes and cytoplasm in ten representative microscopic elds was counted and the percentage of positive cells was calculated. e immunostaining was assessed for staining intensity (grades 0-3) using light microscopy. e criteria used for assessment were as previously reported [19] , where: 0 (negative, ≤5%); 1+ (positive, >5%) of the tumor cells stained.
Statistical analysis
e so ware of SPSS version13.0 for Windows (SPSS Inc, IL, USA) and SAS 9.1 (SAS Institute, NC, USA) was used for statistical analysis. Continuous variables were expressed as mean ± standard error. Statistical analysis was performed with Student's t test, Fisher's exact test for any 2×2 tables, Pearson's χ 2 test for non-2×2 tables, chi-square trend test (the Log Rank, Mantel-Cox) for ordinal datum, Kaplan-Meier and Cox Regression methods for the question of survival analysis. Di erences were considered statistically signi cant when p was less than 0.05. 3.6-20.8 ng/mL).
Results
EMMPRIN mRNA expression
e RNA quality was the same in the matched samples. e mean absorbance ratio at 260 to 280 nm was 2.03 (range: 1.86-2.08). A signi cant increase (Student's t test of paired data, p<0.001) in the EMMPRIN/β-actin ratio in cancerous versus non-cancerous prostate samples was observed ( Figure 1) . A relationship between EMMPRIN expression and clinicopatholologic features was not seen, possibly because of the small sample size and the rather similar clinico-patholologic features.
Expression and location of EMMPRIN in PCa tissues
e expression and distribution of EMMPRIN protein in the tissue samples from 300 patients with PCa (both normal and PCa tissue) were determined using immunohistochemical analysis. EMMPRIN immunoreactivity was detected on all cell membranes and cytoplasm. It was positively, though weakly, stained on a few stromal cells. e positive expression rate of EMMPRIN in PCa patients (186/300, 62.0%) was signicantly higher than that in normal prostate tissues (1/20, 5.0%, Figure 2 . Table 2 displays the correlation among EMMPRIN positive expression rate and various clinicopathological features of patients with PCa. Patients with a high preoperative PSA level (>4 ng/mL) had signi cantly higher EMMPRIN positive expression rate than those with a low PSA level (≤4 ng/mL) (p=0.008). Patients with high clinical stage (p=0.006 for AJCC pathologic (pT) stage) and high-risk tumors (p<0.001) had more intensive EMMPRIN expression. e elevated expression of EMMPRIN was correlated positively with the Gleason score (p<0.001). EMMPRIN staining in primary tumors was signi cantly increased in PCa tissues with positive surgical margin (p<0.001) and positive lymph node (p<0.001).
p<0.001). Representative pictures of immunohistochemistry staining of EMMPRIN are shown in
Correlation between EMMPRIN expression and the clinicopathological characteristics of PCa
EMMPRIN expression and PSA relapse a er radical prostatectomy
To evaluate whether EMMPRIN expression could be used as a potential indicator of clinical outcome a er radical prostatectomy, the available PSA follow-up data from 300 patients a er radical prostatectomy ( relapse-free time was used to indicate progression-free survival. e univariate analyses of the substantial clinico-patholologic parameters proved that the tumor cohort was representatively re ected by a higher risk of PSA relapse time with increased EMMPRIN expression (p=0.003), higher AJCC pathologic (pT) stage (p=0.02), Gleason Score (p=0.008), higher risk classi cation (p<0.001), positive lymph node (p<0.001) and positive surgical margin status (p=0.03, Figure 3 and Table 3 ). Multivariate Cox regression analyses, including the signi cant variables AJCC pathologic (pT) stage (p=0.01), Gleason Score (p=0.01), surgical margin status (p=0.02), risk classi cation (p<0.001) and EMMPRIN expression, con rmed EMM-PRIN as an independent predictor of PSA recurrence.
Discussion
In concordance with previous observation, increased expression of EMMPRIN was observed in a larger number of PCa patients, compared with matching normal prostate tissues, which corresponds to ndings in other tumors such as breast cancer [20] , lung adenocarcinoma [21] , gastric carcinoma [22] and carcinoma of gallbladder [23] . Sample pairs of tumor tissue and normal adjacent tissue of the same patient were also studied and translational con rmation of the transcriptional regulation of EMMPRIN expression was observed. In addition, EMMPRIN staining was observed primarily in the cell membrane and cytoplasm, with a granular pattern and no localization di erences according to the morphologic status of the prostate glands. e heterogeneous staining in tumor tissue was also con rmed. e protein encoded by the EMMPRIN gene is a plasma membrane protein that is important in spermatogenesis, embryo implantation, neural network formation and tumor progression. As a member of the immunoglobulin superfamily, the EMMPRIN protein consists of two IgSF domains, a transmembrane sequence containing a charged residue (Glu) and a cytoplasmic domain of 40 residues, which is why EMMPRIN is localized on the cell membrane and in the cytoplasm. EMMPRIN staining in both the cell membrane and cytoplasm was also described for tissue of breast cancer [20] , lung adenocarcinoma [21] , gastric carcinoma [22] and carcinoma of gallbladder [23] as well. A signi cant increase of EMMPRIN protein expression was seen in 62.0% of patients with PCa, which corresponds to our recently published data of other tumors of urinary system [17, 18] .
is is the rst study that describes EMMPRIN mRNA and protein expression in such a large cohort of patients with PCa, and con rmed the tumor-dependent upregulation of EMMPRIN expression. e hypothesis of EMMPRIN serving as a marker of neoplasia was supported by the ndings of higher EMMPRIN expression in PCa than in adjacent normal tissues. EMMPRIN has characteristics of an adhesive molecule and mediates cell-to-cell or cell-to-matrix adhesion [24] [25] [26] [27] . Some other studies [28] [29] [30] [31] [32] showed that the molecule facilitates the production of MMPs from broblasts and tumor matrix cells; the latter can degrade most components in basal membranes and extracellular matrixes. MMPs may also participate in late events during cancer metastatic spread, when cancer cells enter, survive and exit blood vessels or lymphatics. EMM-PRIN also can a ect expressions of vascular endothelial growth factor (VEGF) at RNA and protein levels, as well as promote the growth of the tumor vascular system [33, 34] . Moreover, EMMPRIN is a multifunctional protein whose functional diversity may relate to distinct post-translational modi cations. Di erential modi cation through glycosylation may be celltype speci c or associated with malignancy [35] .
e correlation between EMMPRIN expression and the clinico-pathologic parameters of patients with PCa supports the suggestion that the over-expression of EMMPRIN is important for the development of this disease. Preoperative PSA levels and AJCC stage were positively correlated with EMM-PRIN expression, which clearly increased with increasing Gleason scores. e similar correlation was seen in other tumors of urinary system with clinical stage.
us, the association of EMMPRIN over-expression and tumor aggressiveness is considered a general phenomenon.
An accurate prediction of the probability of disease recurrence is essential for proper therapy selection. Our nding of EMMPRIN as an independent predictor of PSA recurrence suggests that its expression could be used as an indicator to recognize patients with a high risk of tumor recurrence. In comparison with previous investigations, this study speci cally analyzed the correlation between EMMPRIN expression and PSA recurrence-free survival.
e positive EMMPRIN expression was associated with poor PSA recurrence-free survival in both univariate and multivariate analyses. In univariate analysis, EMMPRIN expression could predict the PSA recurrence-free survival in patients with both low-risk and intermediate-high risk according to the risk classi cation of de ned by D' Amico et al. [36] . In multivariate analysis, no correlation was found between PSA recurrence and high AJCC pathologic (pT) stage, positive surgical margins or lymph node metastasis. In contrast, Gleason score, preoperative PSA level, EMMPRIN expression status and risk classi cation were demonstrated to be independent predictors for PSA recurrencefree survival in PCa patients.
In conclusion, over-expression of EMMPRIN, correlated with the aggressiveness of PCa and the PSA relapse-free time, and may be a novel biomarker of bene t in the follow-up and treatment decisions for PCa. Further studies are recommended to validate the e ciency of EMMPRIN in inhibiting the progression of PCa and to develop drugs that directly target EMMPRIN for the managment of PCa. 
